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MAJOR ARTICLE

Randomized, Parallel Placebo-Controlled
Trial of Primaquine for Malaria Prophylaxis
in Papua, Indonesia
J. Kevin Baird,1 Mark D. Lacy,1 Hasan Basri,1 Mazie J. Barcus,1 Jason D. Maguire,1 Michael J. Bangs,1
Robert Gramzinski,1 Priyanto Sismadi,2 Krisin,1 Judith Ling,1 Iwa Wiady,1 Marti Kusumaningsih,2 Trevor R. Jones,3
David J. Fryauff,3 Stephen L. Hoffman,4 and the United States Naval Medical Research Unit 2 Clinical Trials Teama
1
Parasitic Diseases Program, US Naval Medical Research Unit 2, and 2Infectious Disease Research Center, National Institute of Health Research
and Development, Ministry of Health, Republic of Indonesia, Jakarta, Indonesia; and 3Malaria Program, Naval Medical Research Center, Silver
Spring, and 4Immunotherapeutics, Celera Genomics, Rockville, Maryland

Malaria causes illness or death in unprotected travelers. Primaquine prevents malaria by attacking liver-stage
parasites, a property distinguishing it from most chemoprophylactics and obviating 4-week postexposure
dosing. A daily adult regimen of 30 mg primaquine prevented malaria caused by Plasmodium falciparum and
P. vivax for 20 weeks in 95 of 97 glucose-6-phosphate dehydrogenase (G6PD)–normal Javanese transmigrants
in Papua, Indonesia. In comparison, 37 of 149 subjects taking placebo in a parallel trial became parasitemic.
The protective efficacy of primaquine against malaria was 93% (95% confidence interval [CI] 71%–98%);
against P. falciparum it was 88% (95% CI 48%–97%), and 192% for P. vivax (95% CI 137%–99%). Primaquine
was as well tolerated as placebo. Mild methemoglobinemia (mean of 3.4%) returned to normal within 2 weeks.
Blood chemistry and hematological parameters revealed no evidence of toxicity. Good safety, tolerance, and
efficacy, along with key advantages in dosing requirements, make primaquine an excellent drug for preventing
malaria in nonpregnant, G6PD-normal travelers.
A global resurgence in the incidence and range of malaria, together with deteriorating susceptibility to drugs,
substantially increases risk to travelers [1]. Available
drugs for preventing malaria include chloroquine, chloroquine or atovaquone plus proguanil, mefloquine, and
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doxycycline [2]. The efficacy of chloroquine or chloroquine plus proguanil is rarely 175%. Resistance to
mefloquine occurs in parts of Southeast Asia, and some
travelers tolerate it poorly [3, 4]. Pregnant women or
young children cannot use doxycycline, and it may be
poorly tolerated [5]. Atovaquone plus proguanil has
only recently been licensed for prophylaxis, and there
is limited experience with it. Resistance, contraindications, or poor tolerance limits choices for health care
providers assisting travelers at risk. Poor compliance to
postexposure suppressive prophylaxis accounts for
many cases of malaria among travelers [6, 7]. Travelers
with brief exposure, a week or less, may be especially
unlikely to comply.
Malarone prevents Plasmodium falciparum with only
7 days postexposure dosing [8] by killing liver stage
parasites (i.e., by causal prophylaxis). Early clinical trials
of primaquine [9, 10], since 1950 the only drug recommended for therapy against relapses of malaria,

This article is a U.S. government work, and is not subject to copyright in the United States.

demonstrated causal prophylactic activity against P. falciparum
and P. vivax. Primaquine was not then developed as a chemoprophylactic. Almost universal susceptibility of plasmodia
to weekly chloroquine during the 1960s, and perceived poor
tolerance and toxicity of primaquine [11], overshadowed the
appealing advantages of primaquine for prophylaxis. In 1991,
Hoffman [12] proposed primaquine for prophylaxis, and in
1995 we reported the results of 4 clinical trials in people exposed
to infection in Indonesia and Kenya [13–15]. These trials
showed good tolerance, safety, and efficacy of a 30-mg daily
adult regimen (or 15 mg daily for children). Soto et al. [16]
corroborated those findings in Colombian soldiers. A study of
Israeli travelers by Schwartz and Regev-Yochay [17] affirmed
good effectiveness of the regimen compared to mefloquine or
doxycycline. The present report describes a trial of primaquine
for the prevention of malaria in people lacking clinical immunity who are living in Papua.

SUBJECTS AND METHODS
Study sites. The transmigration villages SP4, SP5, and SP6,
located in the Bonggo district of northeastern Papua (formerly
Irian Jaya), served as study sites. Each village was within 2 km
of the Pacific Ocean and surrounded by dense rain forest.
Homes within the village were of uniform wood plank and tin
roof construction. The total populations of the villages were
∼980, 1410, and 1510 persons, respectively. The residents were
predominantly Javanese (65%) but included people from other
major islands of Indonesia (20%) and people indigenous to the
region (15%). Perennial transmission of P. falciparum, P. vivax,
P. malariae, and P. ovale occurs in the region [18, 19]. The
vectors of malaria, members of the Anopheles punctulatus
group, feed within villages from dusk to dawn and efficiently
transmit malaria [20].
Study subjects. Residents of the study villages between the
ages of 12 and 65 years living in Papua for 13 and !26 months
were eligible for enrollment. Eligible subjects came from Jaya
or other nonendemic areas and had lived in areas free of malaria
for ⭓2 years prior to relocation. Eligible subjects weighed ⭓40
kg. We excluded pregnant or lactating women and those expressing plans to become pregnant. Seven volunteers (0.8%)
who tested positive for glucose-6-phosphate dehydrogenase
(G6PD) deficiency (NADP⫹ spot test, Sigma Chemical) among
the 837 screened were excluded. Volunteers referred to hospital
for treatment of acute or chronic diseases were excluded.
Enrollment.
From April through December 1999, we
screened volunteers for enrollment. Eligible volunteers submitted to a physical examination including measuring vital
signs, palpation of the spleen, and examination by a physician.
Blood cell counts were analyzed (Becton Dickinson QBCII Plus
Analyzer system and reagents), as were blood chemistries (Ko-

dak VITROS DTII). Women of childbearing age were asked to
contribute a urine specimen for pregnancy testing by analysis
for human chorionic gonadotropin (HCG; Abbott Laboratories). A total of 837 volunteers were screened, and 421 were
enrolled for treatment against both the blood and liver stages
of the parasite (hereafter referred to as “radical cure”). Plans
to leave the study area, history of recent residence in an endemic
area, or unwillingness to provide consent to participate constituted the 3 most common reasons for exclusion (29%, 24%,
and 11% of exclusions, respectively).
Radical cure. The subjects received directly observed, signature-affirmed radical curative therapy with atovaquoneproguanil (tablets combining 250 mg atovaquone ⫹ 100 mg
proguanil hydrochloride; Malarone; GlaxoSmithKline) and
primaquine phosphate (Sanofi-Winthrop). The cure consisted
of single daily doses of 4 tablets of atovaquone-proguanil on
days 0, 1, and 2, followed by single daily doses of 30 mg
primaquine base (2 tablets) on days 3–16.
Randomization. A total of 394 subjects completed radical
cure with adequate compliance: 385 missed no dose; 6 missed
a single dose of primaquine; 2 missed 2 doses of primaquine;
and 1 missed 3 doses of primaquine. Randomization of subjects
occurred on the last day of radical cure. The clinical statistics
department at Glaxo Wellcome (USA) generated a randomization code assigning sequential numbers to either inclusion
in a parallel double-blind, placebo-controlled trial of atovaquone-proguanil for prophylaxis or exclusion from that trial
in a 3:1 ratio. The 97 subjects randomized to exclusion were
offered the opportunity to enter the open label trial of primaquine prophylaxis and all accepted. These subjects again
provided informed consent specific to that study and began
prophylaxis the following day.
Prophylaxis. The study drug was 15 mg of primaquine
base as phosphate salt in a coated, unscored tablet (SanofiWinthrop). The drug was dispensed to health workers on a
daily basis. Each health worker was assigned 8–12 subjects and
tasked with visiting their homes each morning to administer
the drug with morning meal. A packet of 3 cookies was provided with each dose (30 mg primaquine base as a single daily
dose). The health worker and subject verified compliance by
signatures on a dosing card. At the end of each day, supervisors
crosschecked the signatures of dosing cards and affirmed agreement by signing a record sheet.
Any complaint consistent with onset of malaria (i.e., headache, fever, chills, nausea, vomiting, or malaise) prompted an
immediate blood film examination. Routine blood films were
collected once a week, regardless of symptoms. Female subjects
of childbearing age donated a urine sample for monthly HCG
testing, or any time pregnancy was suspected. We evaluated a
sample of venous blood for hematological and blood chemistry
parameters at weeks 4 and 20 of prophylaxis.
Primaquine Prophylaxis for Malaria • CID 2001:33 (15 December) • 1991

Table 1.
groups.

Demographic characteristics of patients in study

Variable

Primaquine
(n p 97)

Placebo
(n p 149)

P

Mean age in years (range)

33.3 (14–60)

33.6 (12–60)

.808

Mean weight in kg
(range)

51.4 (40–73)

51.2 (40–71)

.814

Male:female

61:36

101:48

.43

Mean exposure, monthsa

20.8

20.5

.26

b

15 (0.155)

27 (0.181)

.59

Dropout rate
a

Time resident in Papua prior to enrollment.
Subjects lost to follow-up for reasons other than study end points during
prophylaxis.
b

End points. Prophylaxis continued for 20 weeks or until
a subject had a blood film positive for plasmodia. Study microscopists were examined and certified to be 195% sensitive
and 100% specific in diagnosis of a set of 25 slides containing
confirmed negative or positive blood films ascertained by 3
expert microscopists, each with 120 years of experience. Study
microscopists read 200 ocular fields of Giemsa-stained thick
films magnified to 1000⫻ by standard oil immersion light microscopy. A second microscopist affirmed positive blood films.
A third expert microscopist adjudicated discordant readings.
Parasitemia density was calculated as parasites per 200 WBCs
Table 2.

in the thick film ⫻ 8000 WBCs/mL whole blood. Subjects positive for plasmodia received atovaquone-proguanil (as per radical cure) and were dropped from the study after successful
therapy was affirmed with 28 days follow-up. Subjects missing
12 doses primaquine in any 7-day period were considered noncompliant and dropped from the study. Subjects leaving the
study site for ⭐7 days took along a travel pack containing daily
primaquine and a signature card. Travel for 17 days prompted
withdrawal from the study.
Postprophylaxis follow-up. Subjects completing 20 weeks
of prophylaxis were followed for 4 weeks. Blood film samples
were examined at 2 and 4 weeks. A 100-mL sample of peripheral
blood was taken by finger stick from subjects on the last day
of primaquine or placebo prophylaxis and then daily for 18
days. We measured levels of total hemoglobin, oxyhemoglobin,
and methemoglobin from these samples, using a co-oximeter
(OSM3, Radiometer Copenhagen) within 30 min of collection.
Statistical analyses. The primary end point of the study
was parasitemia. Protective efficacy was defined as (1 ⫺ incidence densitydrug/incidence densityplacebo) ⫻ 100. Adverse events
were reported as incidence density, or the number of events
per person-time of follow-up. Differences in means were assessed using the paired or unpaired Student’s t test, or Mantel
Haenszel test. P values ⭐.05 were considered significant. Anal-

Adverse events during 20 weeks of daily primaquine prophylaxis.
Placebo

Primaquine
Adverse event

No. of
events

Incidence
density

No. of
events

Incidence
density

RR

95% CI

P

Headache

34

1.01

74

1.63

0.62

0.41–0.93

.02

Abdominal pain

34

1.01

33

0.73

1.39

0.86–2.23

.18

Cough

31

0.92

84

1.85

0.50

0.33–0.74

!.001

Nausea

20

0.59

34

0.75

0.79

0.46–1.38

.41

Dizziness

19

0.56

19

0.42

1.35

0.72–2.53

.36

Neck/back pain

18

0.53

19

0.42

1.28

0.67–2.42

.46

Cold/flu

18

0.53

30

0.66

0.81

0.45–1.45

.47

Pruritis

15

0.45

30

0.66

0.67

0.36–1.25

.21

Myalgia

15

0.45

22

0.49

0.92

0.47–1.78

.80

Fever

14

0.42

29

0.64

0.65

0.35–1.23

.18

Malaise

12

0.33

14

0.31

1.15

0.54–2.48

.72

Arthralgia

12

0.36

21

0.46

0.77

0.38–1.56

.47

Diarrhea

9

0.27

13

0.29

0.93

0.39–2.20

.87

Vomiting

9

0.27

8

0.18

1.51

0.59–3.89

.39

Chills

7

0.21

5

0.11

1.88

0.61–5.82

.27

Chest pain

6

0.18

6

0.13

1.35

0.44–4.14

.61

Sore throat

6

0.18

24

0.53

0.34

0.14–0.79

.01

Respiratory difficulty

5

0.15

15

0.33

0.45

0.17–1.20

.11

Anorexia

4

0.12

2

0.04

2.69

0.53–13.7

.23

Insomnia

5

0.15

3

0.07

2.24

0.56–9.0

.26
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Table 3.

Findings of hematological assays (mean  SD) among subjects taking primaquine or a parallel placebo.
Week 4

Enrollment
Placebo
(n p 149)

Primaquine
(n p 97)

Total lymphocytes ⫹ monocytes ⫻ 109 cells/L

3.68  1.3

Lymphocytes ⫹ monocytes, %

40.2  8.9
5.7  2.0
59.8  8.9

Parameter

Total granulocytes ⫻ 10 cells/L
9

Granulocytes, %

Week 20

Placebo
(n p 137)

Primaquine
(n p 92)

Placebo
(n p 116)

Primaquine
(n p 82)

3.63 1.3

3.38  1.1

3.09  0.96

3.07  1.21

2.79  0.86

41.3  10.7

38.8  8.7

36.3  8.1

38.1  10.6

35.9  7.6

5.36  1.8

5.6  1.8

5.57  1.9

5.16  2.1

5.11  1.5

58.7  10.8

61.3  8.2

63.7  8.1

61.6  10.2

64.1  7.6

Total WBCs ⫻ 109 WBCs/L

9.37  2.7

8.99  2.5

8.92  2.4

8.64  2.4

8.2  2.6

7.9  1.9

Hemoglobin, g/dL

13.4  1.5

13.4  1.8

13.6  1.3

13.3  1.5

13.5  1.5

13.1  1.4

Hematocrit level, %

41.1  4.7

41.2  5.4

43.8  4.2

42.7  4.4

42.4  3.8

41.4  3.5

Platelets ⫻ 109 platelets/L

264  74

271  91.3

271  86

256  75.2

254  95

248  77

yses were carried out using SPSS (version 9.0; SPSS) and Epi
Info (version 6.04; Centers for Disease Control and Prevention).
RESULTS
Compliance. Fifteen (16%) of 97 subjects taking primaquine
and 27 (18%) of 149 taking placebo withdrew from the study
before reaching an end point. The week of withdrawal from
the primaquine group ranged from 1 to 19 (median, week 10).
The subjects contributed person-time at risk applied to tolerance, toxicity, and efficacy estimates up to point of withdrawal.
Reasons cited for dropping subjects included withdrawal of
consent (13) and failure to comply with protocol (2). One of
the noncompliant subjects left the study site for 11 week, and
he developed P. falciparum upon return. The other missed medication more than twice in 1 week. No subject cited adverse
events as the basis of withdrawal. The 16% dropout rate (excluding malaria) was similar to the 18% rate among subjects
receiving placebo (P p .59 ; table 1). Excluding dropped subjects, 12,233 doses were scheduled, and 12,201 (99.8%) were
delivered.
Tolerability. No adverse event prompted withdrawal from
the study, and no serious adverse events occurred. Table 2 lists
the 20 most frequent adverse events. The only adverse events
with statistically significant relative risk (primaquine compared
to parallel placebo; P ! .05 ) were headache (RR p 0.62), cough
(RR p 0.50), and sore throat (RR p 0.34). RR ! 1.0 indicates
lesser risk in the primaquine group. Among the 17 other adverse
events, no RR was significant. Among all 40 adverse event
classifications evaluated with a total of 933 complaints registered, the RR in the primaquine group was 0.80 (95% CI
0.70–0.92; P p .001).
Hematological parameters. No hematological test outcome prompted withdrawal from the study in any subject taking prophylaxis. Table 3 summarizes hematological tests of subjects taking primaquine prior to radical cure, and at weeks 4

and 20 of prophylaxis. The difference between some values was
statistically significant: mean total lymphocyte counts, mean %
lymphocytes and monocytes, % granulocytes, and total WBC
count. No difference was considered clinically significant, and
all other comparisons showed no other statistically significant
differences. The same was true for subjects receiving placebo,
except statistically significant differences occurred with mean
hematocrit level (%), total lymphocytes ⫹ monocytes, total
WBCs, and platelet count. In the statistical comparison of these
parameters between subjects taking primaquine and placebo at
baseline, week 4 and week 20, significant differences appeared
between mean total lymphocytes ⫹ monocytes, and mean total
platelets. No difference was considered clinically significant.
Blood chemistry parameters. No blood chemistry test result prompted withdrawal of study subjects taking prophylaxis.
Table 4 summarizes blood chemistry findings among subjects
taking primaquine at enrollment, week 4, and week 20. Among
the 4 significant differences from baseline (2 at week 4 and 2 at
week 20) in mean sodium, potassium, albumin, and creatinine,
respectively, none appeared clinically significant. The same was
true for the placebo group for mean potassium, bilirubin (week
4), and glucose (week 20). All other comparisons between means
at enrollment and week 4 and 20 for either primaquine or placebo
were not significant (P values ranged from .051 to .99). Comparisons of primaquine to placebo matched at baseline, week 4,
and week 20 again showed no statistically significant differences,
except between a minority of clinically insignificant distinctions
(for sodium and bilirubin).
Methemoglobinemia. No subject complained of symptoms
attributable to methemoglobinemia during the course of radical
cure or prophylaxis. Figure 1 illustrates mean measurements of
total, oxyhemoglobin, and methemoglobin among subjects taking primaquine beginning on the last day of prophylaxis. The
graph reveals essentially normal levels of total and oxyhemoglobin through the 18 days of measurements and a mild methemoglobinemia (mean 3.5% of total hemoglobin, not exceeding
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Table 4. Findings of blood chemistry assays (mean  SD) among subjects taking primaquine or a
parallel placebo.
Enrollment

Week 4

Week 20

Parameter

Placebo
(n p 149)

Primaquine
(n p 97)

Placebo
(n p 137)

Primaquine
(n p 92)

Placebo
(n p 116)

Primaquine
(n p 82)

Sodium, meq/L

138  4.0

138  3.6

140  4.1

140  6.3

137  3.6

139  3.2

Potassium, meq/L

3.69  0.4

3.64  0.5

3.83  0.4

3.79  0.4

3.79  0.4

3.64  0.30

Albumin, g/dL

4.15  0.4

4.16  0.4

4.21  0.4

4.15  0.3

4.06  0.4

4.00  0.40

Creatinine, mg/dL

1.12  0.2

1.13  0.2

1.08  0.2

1.07  0.2

1.1  0.2

Glucose, mg/dL

91.0  20

91.9  21

94.2  22

94.6  17

102  24

96.5  19

Total bilirubin, mg/dL

0.42  0.2

0.47  0.3

0.30  0.2

0.53  0.6

0.43  0.3

0.42  0.3

Alk phosphatase, U/L

84.1  26

76.8  23

87.9  35

84.4  35

84.1  26

76.8  24

ALT (SGPT), U/L

17.4  10

18.8  13

16.7  12

18.6  10

18.6  10

18.5  7.7

NOTE.

1.1  0.20

Alk, alkaline; ALT (SGPT), alanine aminotransferase (serum glutamic pyruvic transaminase); meq, milliequivalents.

8.5%) on the last day of prophylaxis resolving by day 18. At day
28, the mean methemoglobinemia among 72 subjects was 0.5%,
not exceeding 0.8%. The highest methemoglobin among any
subject was 8.5% on the last day of prophylaxis.
Efficacy.
Table 5 summarizes infections by plasmodia
among study subjects. A total of 39 infections occurred among
subjects taking placebo, 23 by P. falciparum and 16 by P. vivax.
Two subjects had mixed infections by P. falciparum and P. vivax,
and each infection counted among others of the same species.
Two infections by P. falciparum occurred among compliant
subjects taking primaquine prophylaxis. Protective efficacy
against P. falciparum was estimated at 88% (95% CI 48%–97%).
No infections by P. vivax occurred among primaquine-compliant subjects. The estimate of protective efficacy for P. vivax,
192% (95% CI 137%–99%) assumed a single infection. The
protective efficacy against plasmodia of either species was 93%
(95% CI 71%–98%).
No evidence of rebound parasitemia appeared among subjects finishing the 20 weeks of primaquine. Postprophylaxis
follow-up for 4 weeks revealed 1 parasitemia (P. falciparum
during week 4) among the 77 at risk in the primaquine group.
This was not significantly different from the 3 postprophylaxis
parasitemias occurring in the 85 subjects completing placebo.
Illness on the day of parasitemia documented the nonimmune status of study subjects. Among the 37 subjects with
slide-proven malaria, 21 (57%) had documented fever (axillary
temperature 137.5C), and 33 (89%) complained of fever, chill,
headache, nausea, vomiting, myalgia, or malaise (table 6).

no subject was removed from the study because of intolerance
or evidence of toxicity. Subjects taking primaquine registered
complaints of adverse events less often than did subjects in a
parallel placebo group (RR p 0.80; 95% CI 0.70–0.92; P p
.001). Most hematological and blood chemistry parameters before prophylaxis were indistinguishable from those measured
after 4 or 20 weeks. The few differences noted were between
means within normal ranges. The same was true of hematological values (tables 3 and 4). Mild methemoglobinemia on
the last day of prophylaxis resolved within 18 days. Methemoglobinemia after 52 weeks [15] or 20 weeks of 30 mg primaquine daily was no more pronounced than in subjects receiving standard 15 mg daily for 14 days [21]. The risk of
methemoglobinemia did not increase with duration of dosing.
Methemoglobin levels observed in this study did not approach
the 20%–30% level considered the threshold at which symp-

DISCUSSION
A 30-mg daily adult regimen of primaquine provided welltolerated, safe, and efficacious protection against P. falciparum
and P. vivax for 20 weeks in G6PD-normal people living in
northeastern Papua. No serious adverse events occurred, and
1994 • CID 2001:33 (15 December) • Baird et al.

Figure 1. Mean levels of total hemoglobin (Hgb g/dL []), oxyhemoglobin (HgbO2 g/dL []) and methemoglobin (metHgb; % of total Hgb
[⫻]) among a median of 22 measurements per data point (range, 2–72).
Bars indicate 95% confidence limits for mean total Hgb and HbgO2 and
mean % metHgb with upper range shown in the bar.

Table 5.

Protective efficacy of 30 mg of primaquine given daily for 20 weeks.
Person-years
at risk

Variable

33.7

2

0

2

45.3

23

16

39

—

88 (48–97)

192 (137–99)

93 (71–98)

Illness with slide-proven malaria.
Infection
Plasmodium
falciparum

Plasmodium
vivax

Reported

1

0

0

Not reported

1

0

0

19

11

2

2

3

0

20

11

2

3

3

0

87

79

100

Mixed

Primaquine

Placebo
Not reported
Either
Reported
Not reported
Ill, %

a

Assumes a single infection by P. vivax.

toms such as dyspnea or nausea occur [22]. Contrary to oftencited reports [11, 23], primaquine caused no more stomach
upset than did placebo (table 2). We attributed this to administration of drug with food. Clayman et al. [24] demonstrated
relief from even severe stomach upset with extraordinary doses
of primaquine (⭐240 mg) by administration with food.
The protective efficacy of 30 mg daily primaquine against
infection by plasmodia was 93% (95% CI 71%–98%). An earlier
trial in 43 subjects for 52 weeks in the same region [15] showed
92% efficacy (95% CI 79%–99%). Soto et al. [16] reported
89% protective efficacy (95% CI 75%–96%) against infection
of 167 Colombian soldiers for 16 weeks. Weiss et al. [14] evaluated 15 mg daily in 32 Kenyan children and measured a protective efficacy against P. falciparum of 85% (95% CI
67%–94%). Randomized, placebo-controlled clinical trials of
daily primaquine in 339 subjects living in Southeast Asia, South
America, and Africa demonstrate consistently excellent protective efficacy. Corroboration of the earlier trials by our findings
confirms the excellent protective efficacy and good safety and
tolerability of daily primaquine for preventing P. falciparum
and P. vivax in travelers. Moreover, Schwartz and Regev-Yochay
[17] reported superior effectiveness of the 30 mg daily primaquine regimen compared to mefloquine or doxycycline in
Israeli travelers.
Available data demonstrate the necessity of 30 mg daily as
the adult dose for good protective efficacy. When Arnold et al.
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[10] tried a daily 15-mg dose against challenge by P. vivax, the
protective efficacy was 80% (8 of 10 subjects protected) compared to 100% (10 of 10 protected) for 30 mg daily. When
they gave a single 15-mg dose the day following challenge with
P. falciparum, the protective efficacy was 40% (4 of 10 protected) compared to 100% (10 of 10 protected) for the single
30-mg dose [9]. When Powell et al. [25] challenged 3 subjects
taking daily 30 mg primaquine, none became parasitemic; however, 1 of 3 subject taking 15 mg daily became parasitemic.
When we evaluated a 30-mg regimen on alternate days in Indonesia (n p 45), the protective efficacy was just 74% (95%
CI 21%–94%) against P. falciparum [12]. A similar alternate
day regimen evaluated by Weiss et al. [14] showed 0% (95%
CI 0%–50%) protective efficacy against P. falciparum in 39
Kenyan children.
Primaquine substantially improves the range of chemoprophylactic options for preventing malaria in travelers. The primary advantage over currently available suppressive prophylactics such as mefloquine or doxycycline is freedom from the
necessity of 4 weeks of postexposure prophylaxis. Travelers often fail to comply with a lengthy postexposure dosing regimen
[26–29]. This may be especially true of travelers who have had
relatively brief periods of exposure to risk of infection. Travelers
facing risk of infection spanning just a few days may be unlikely
to accept and comply with a regimen of 4 weeks of postexposure
dosing. Primaquine offers these travelers a dosing regimen that
spans the period of exposure and just 2–6 days after returning
home. Finally, a loading regimen of primaquine is not necessary.
The safe limit of duration of prophylaxis using primaquine
has not been firmly established. Randomized trials of daily
primaquine for prophylaxis have ranged from 12 to 52 weeks
[13–16]. No complaint became more frequent as the cumulative
dose increased. Methemoglobinemia did not increase after 20
(figure 1) to 52 weeks [15] of daily dosing compared to the
standard 14-day treatment regimen [19]. Except for the 42
subjects taking daily primaquine for 52 weeks, all other studies
have spanned 12–20 weeks of daily dosing. Therefore, the safe
duration of primaquine dosing may be estimated between 12
and 20 weeks.
In summary, a 30-mg daily adult regimen of primaquine provided well-tolerated, safe, and efficacious prophylaxis against P.
falciparum and P. vivax for 20 weeks among nonimmune people
Primaquine Prophylaxis for Malaria • CID 2001:33 (15 December) • 1995

living in endemic Papua. The findings corroborate trials in a
nearby area, in mesoendemic South America, and in holoendemic Africa [13–17]. Primaquine offers health care providers
an excellent option to standard suppressive prophylactics for
travelers exposed to malaria. Primaquine should not be used by
pregnant women, because of the risk to the fetus of hemolysis
with G6PD deficiency, and prescribing primaquine for prophylaxis should only follow laboratory ascertainment of a normal
G6PD phenotype.
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